July 21, 2025 / 12:00 PM ET – 1:00 PM ET
Sponsored by: This activity is supported by an educational grant from Sanofi US.
PROGRAM DESCRIPTION
This virtual symposium will overview the benefits of screening for type 1 diabetes (T1D), as well as evidence-based screening and early detection methods to identify presymptomatic T1D in order to intervene early with disease-modifying therapies (DMTs) to delay disease progression. In addition, through expert faculty conversations, high impact animations, and patient cases, this activity will provide valuable insights to pediatric endocrinologists and other clinicians that see T1D patients on identifying appropriate patients who would benefit from treatment with DMTs, as well as considerations for administration of these therapies according to guidance and patient-specific factors.
Learning objectives:
- Incorporate evidence-based strategies for presymptomatic T1D screening into routine clinical practice to improve early detection
- Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions
- Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence
- Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors
SPEAKERS:
- Ananta Addala, DO, MPH
Assistant Professor
Department of Pediatrics
Division of Endocrinology & Diabetes
Lucile Packard Children’s Hospital
Stanford University - Laura Jacobsen, MD
Assistant Professor
Associate Fellowship Program Director
Pediatric Endocrinology
University of Florida
Gainesville, FL
This activity is supported by an educational grant from Sanofi US.